Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Recap: Phathom Pharmaceuticals Q3 Earnings

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:00 AM. Here’s what…
byBenzinga Insights
November 9, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:00 AM.

Here’s what investors need to know about the announcement.

Earnings

Phathom Pharmaceuticals beat estimated earnings by 14.61%, reporting an EPS of $-0.76 versus an estimate of $-0.89.

Revenue was down $0 from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.16 which was followed by a 0.67% drop in the share price the next day.

** Listen to the earnings announcement yourself by clicking here. **

To track all earnings releases for Phathom Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

CBD Giant’s Challenging Year: Q4 Net Sales Slide By 27% But Net Loss Narrows 67% YoY

By Jelena Martinovic
December 26, 7:05 PM
cbdMD reported a 27% year-over-year drop in net sales for the fourth quarter of 2023, totaling $5.7 million. The company attributed the decline to industry trends, reduced marketing spend, and lower wholesale pricing for its new high-strength products. For the full fiscal year 2023, net sales reached $24.2 million, down from $35.4 million in the previous year. Gross profit for the year was approximately $15 million, a decrease from $22.3 million in fiscal 2022. The company reported a net loss of about $23 million, compared to $70 million in 2022. Operating expenses fell to $24.2 million from $40 million in the prior year. cbdMD's working capital on September 30, 2023, was $3.4 million, down from $10.7 million on the same date in 2022. The company also launched its hempMD and ATRx brands in 2023, expanding its product channels into Amazon and other consumer products channels.

YCBD